In experiment 2b, in order to assess the infarct volume with or without systemic manganese (Mn) administration at 2 days after transient middle cerebral artery occlusion (tMCAO), coronal T2-weighted MRI was performed in addition to T1-weighted MRI to all mice at 3, 7, 10, 14 and 21 days after tMCAO. A rapid-acquisition-with-relaxation-enhancement (RARE) pulse sequence was acquired for T2-weighted MRI under the same dimensions as T1-weighted MRI, with repetition time/echo time = 6500/120 ms, RARE factor = 12, and number of averages = 4. The total brain volumes and the total infarct volumes indicated by T2-weighted hyperintensity were measured in the tMCAO mice using ImageJ v1.44 (Wayne Rasband, NIH, USA). Volumetric values were compared between ipsilesional and contralesional hemispheres using two-tailed Student's t-tests. At 5 months after tMCAO, axial T2-weighted MRI was also performed to the remaining mice to qualitatively assess the brain morphology.
METHODS
In experiment 2b, in order to assess the infarct volume with or without systemic manganese (Mn) administration at 2 days after transient middle cerebral artery occlusion (tMCAO), coronal T2-weighted MRI was performed in addition to T1-weighted MRI to all mice at 3, 7, 10, 14 and 21 days after tMCAO. A rapid-acquisition-with-relaxation-enhancement (RARE) pulse sequence was acquired for T2-weighted MRI under the same dimensions as T1-weighted MRI, with repetition time/echo time = 6500/120 ms, RARE factor = 12, and number of averages = 4. The total brain volumes and the total infarct volumes indicated by T2-weighted hyperintensity were measured in the tMCAO mice using ImageJ v1.44 (Wayne Rasband, NIH, USA). Volumetric values were compared between ipsilesional and contralesional hemispheres using two-tailed Student's t-tests. At 5 months after tMCAO, axial T2-weighted MRI was also performed to the remaining mice to qualitatively assess the brain morphology.
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RESULTS
When evaluating the infarct volumes indicated by hyperintensity in T2-weighted MRI, no apparent difference was found in the ipsilesional forebrain between tMCAO models with and without systemic Mn administration ( Supplementary Fig. S1a and S1c). In the posterior brain regions remote to the ischemic core, T2-weighted hyperintensity was also observed in the hippocampus and the subcortical structures in all tMCAO animals without systemic Mn administration. However, animals that had received systemic Mn administration at 2 days after tMCAO showed no apparent T2-weighted hyperintensity in the posterior brain at Day 3 or beyond (Supplementary Fig. S1b and S1d). At 5 months after tMCAO, shrinkage of the midbrain and the superior and inferior colliculi was observed in all the 2 remaining animals without systemic Mn administration, but not in animals with systemic Mn administration at 2 days after tMCAO ( Supplementary Fig. S2 ).
DISCUSSION
Upon tMCAO, it has been recognized that brain regions remote to the striatum are less susceptible to oxidative stress 1 and may undergo later onsets for neuronal death due to ischemia and reperfusion [2] [3] [4] . While Mn is known to be neurotoxic at high doses, several studies showed the therapeutic potentials of Mn at low doses 5, 6 . For example, a Mn complex with a ligand containing oxidizable quinol group demonstrate the potential to concurrently visualize and alleviate oxidative stress 7 . Given that Mn triggered the scavenging of superoxide and hydroxyl radicals6, whereby Mn superoxide dismutase and glutamine synthetase activities may increase upon MnCl2 administration to normal and ischemic animals 6, 8, 9 , it is possible that systemic Mn administration at 2 days after tMCAO could exert antioxidative effects to some extents, and preserve brain tissues 3 at remote sites from delayed secondary damage. To test this hypothesis, we performed T2-weighted MRI immediately after T1-weighted MRI at each time point to all tMCAO mice, and evaluated the cerebral infarction indicated by T2-weighted hyperintensity 10, 11 . We observed a significant reduction in infarct volumes in the posterior brains of the Mn-treated tMCAO mice compared to the untreated tMCAO mice (Supplementary Fig. S1 ). This effect was further supported by T2-weighted MRI of the remaining unsacrificed animals at 5 months after tMCAO, showing obvious shrinkage of the midbrain without systemic Mn administration but not in animals with Mn administration at 2 days after tMCAO ( Supplementary Fig. S2 ). Recent studies have shown marked neuroprotective effects of Mn complexes against focal ischemic insults up to 6 hours after ischemia 12, 13 . The results of this study illustrated the potential neuroprotective effects 
